[go: up one dir, main page]

DK1007082T3 - Modificeret tumor nekrose faktor - Google Patents

Modificeret tumor nekrose faktor

Info

Publication number
DK1007082T3
DK1007082T3 DK98904563T DK98904563T DK1007082T3 DK 1007082 T3 DK1007082 T3 DK 1007082T3 DK 98904563 T DK98904563 T DK 98904563T DK 98904563 T DK98904563 T DK 98904563T DK 1007082 T3 DK1007082 T3 DK 1007082T3
Authority
DK
Denmark
Prior art keywords
tnf
necrosis factor
tumor necrosis
modified tumor
range
Prior art date
Application number
DK98904563T
Other languages
English (en)
Inventor
Mike A Clark
Original Assignee
Phoenix Pharmacologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Pharmacologics Inc filed Critical Phoenix Pharmacologics Inc
Application granted granted Critical
Publication of DK1007082T3 publication Critical patent/DK1007082T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98904563T 1997-01-15 1998-01-15 Modificeret tumor nekrose faktor DK1007082T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3552197P 1997-01-15 1997-01-15
US681098A 1998-01-14 1998-01-14
PCT/US1998/000683 WO1998031383A1 (en) 1997-01-15 1998-01-15 Modified tumor necrosis factor

Publications (1)

Publication Number Publication Date
DK1007082T3 true DK1007082T3 (da) 2007-02-19

Family

ID=26676095

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98904563T DK1007082T3 (da) 1997-01-15 1998-01-15 Modificeret tumor nekrose faktor

Country Status (11)

Country Link
US (1) US7785579B2 (da)
EP (1) EP1007082B1 (da)
JP (1) JP4295831B2 (da)
CN (1) CN1168495C (da)
AT (1) ATE342729T1 (da)
AU (1) AU725133B2 (da)
CA (1) CA2277757C (da)
DE (1) DE69836222T2 (da)
DK (1) DK1007082T3 (da)
ES (1) ES2275300T3 (da)
WO (1) WO1998031383A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP1588716B1 (en) 1998-08-06 2011-02-16 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
CN1315351A (zh) * 2000-03-24 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人一种组织或发育阶段特异转录因子相关因子11和编码这种多肽的多核苷酸
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
JP2004528025A (ja) * 2001-02-21 2004-09-16 サーロメッド・インコーポレーテッド 修飾されたアネキシン蛋白質及び血栓症を防ぐための方法
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
AU2004297228A1 (en) 2003-12-03 2005-06-23 Nektar Therapeutics Al, Corporation Method of preparing maleimide functionalized polymers
JP4877225B2 (ja) 2005-02-18 2012-02-15 日油株式会社 ポリオキシアルキレン誘導体
LT3321359T (lt) 2005-04-11 2021-05-10 Horizon Pharma Rheumatology Llc Urato oksidazės variantinės formos ir jų panaudojimas
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
TW200716751A (en) 2005-04-11 2007-05-01 Savient Pharmaceuticals Inc A variant form of urate oxidase and use thereof
KR101288027B1 (ko) 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
KR100886783B1 (ko) * 2006-06-12 2009-03-04 성균관대학교산학협력단 N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
CN101837130B (zh) * 2009-03-20 2013-10-23 北京大学 聚乙二醇-二肽-抗肿瘤药物复合物及其用途
US20100284962A1 (en) * 2009-05-06 2010-11-11 Oncopharmacologics, Inc. Modified tumor necrosis factor-beta
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US10640804B2 (en) 2013-03-14 2020-05-05 Ran Biotechnologies, Inc. Methods and materials for detection of biologicals
WO2014151836A1 (en) 2013-03-14 2014-09-25 Ran Biotechnologies, Inc. Methods and materials for microorganism capture
CN105294852B (zh) * 2015-10-27 2019-06-07 岳阳新华达制药有限公司 聚乙二醇与肿瘤坏死因子α或其类似物的偶联物及其医药用途
JP6797203B2 (ja) 2015-12-17 2020-12-09 ザ・ジョンズ・ホプキンス・ユニバーシティー デスレセプターアゴニストによる全身性硬化症の改善
US11084879B2 (en) 2016-04-07 2021-08-10 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5447722A (en) 1983-12-12 1995-09-05 University Of Manitoba Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
WO1990005534A1 (en) 1988-11-23 1990-05-31 Genentech, Inc. Polypeptide derivatives
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols

Also Published As

Publication number Publication date
ATE342729T1 (de) 2006-11-15
CN1243444A (zh) 2000-02-02
JP4295831B2 (ja) 2009-07-15
AU6241098A (en) 1998-08-07
EP1007082A4 (en) 2004-05-12
DE69836222T2 (de) 2007-11-15
US7785579B2 (en) 2010-08-31
EP1007082B1 (en) 2006-10-18
AU725133B2 (en) 2000-10-05
JP2001511784A (ja) 2001-08-14
EP1007082A1 (en) 2000-06-14
WO1998031383A1 (en) 1998-07-23
ES2275300T3 (es) 2007-06-01
US20060222626A1 (en) 2006-10-05
CA2277757C (en) 2008-09-16
CN1168495C (zh) 2004-09-29
CA2277757A1 (en) 1998-07-23
DE69836222D1 (de) 2006-11-30

Similar Documents

Publication Publication Date Title
DK1007082T3 (da) Modificeret tumor nekrose faktor
HK1022810A1 (en) Method of treating endothelial injury
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
ES2175460T3 (es) Compuesto de lipoxinas y su utilizacion en el tratamiento de patologias con proliferacion celular.
NZ337845A (en) Non-antigenic branched polymer conjugates
CA2092271A1 (en) Use of g-csf for treating taxol side-effects
GR3025333T3 (en) Cross-linking agent
CA2291065A1 (en) Raf kinase inhibitors
CA2174325A1 (en) Non-antigenic branched polymer conjugates
EA200100954A1 (ru) Производные камптотецина, обладающие противоопухолевой активностью
DE69737995D1 (de) INSULINPREPARATION MIT MAnnitol
GR3015431T3 (en) Use of acetyl L-carnitine in the therapeutic treatment of coma.
EP0344880A3 (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
DK0531413T3 (da) Et antiviralt præparat indeholdende prostratin
SE8000466L (sv) Polymeriska immunreglerade medel
TR199801732T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
NO995944L (no) Anti-arrytmisk blanding og fremgangsmåter for behandling
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
ATE91237T1 (de) Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen.
GR890100563A (el) Προαγωγη της αναπτυξεως χοιρων.
EP0378146A3 (en) Polyamine derivatives as antineoplastic agents
DE3473826D1 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
GB2208798B (en) Anti-cancer agent comprising l-ascorbic acid and o-benzylidene-l-ascorbic acid or deuterated derivative
JPS6461429A (en) Remedy for cancer
DK0711163T3 (da) Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF